Bright Minds Biosciences PEG Ratio

Bright Minds Biosciences (DRUG) currently reports a PEG ratio of -11.34. That is below the Healthcare sector average of 11.52. Use the charts on this page to explore Bright Minds Biosciences's PEG ratio history and peer comparisons.

Bright Minds Biosciences's PEG ratio of -11.34 is lower than the Healthcare sector average of 11.52. That is roughly 198.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Bright Minds Biosciences's market price to a fundamental measure such as earnings, sales, or book value. At -11.34, DRUG can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of -11.34, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.52. From there, open related valuation or income-statement pages for Bright Minds Biosciences, and consider following DRUG for alerts when major investors trade the stock.

Bright Minds Biosciences is classified in the Healthcare sector. On PEG ratio, it currently shows -11.34 versus a sector average near 11.52. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DRUG with unrelated industries.